Advertisement

Breast Cancer

, 6:275 | Cite as

Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next

  • Diana M. Barnes
Special Lecture
  • 35 Downloads

Key words

Immunohistochemistry SPF Prediction Prognostic Response 

Abbreviations

ER

Estrogen receptor

SPF

S-phase fraction

IHC

Immunohistochemistry

EIA

Enzyme immunoassay

ICRF

Imperial Cancer Research Fund

DCIS

Ductal carcinomain situ

CGH

Comparative genomic hybridization

FISH

Fluorescentin situ hybridization

References

  1. 1).
    Jensen EV, DeSombre ER: Steroid hormone binding and hormone receptor. In: Holland JF, Frie E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR eds, Cancer Medicine, Lea & Febinger, Philadelphia, pp815–823, 1993.Google Scholar
  2. 2).
    Barnes DM, Harris WH, Smith P,et al: Immunohistochemical determination of oestrogen receptor; Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.Br J Cancer 74:1445–1451, 1996.PubMedGoogle Scholar
  3. 3).
    Miles DW, Harris WH, Gillett CE,et al: The effect of cerbB2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant CMF. Int J Cancer 84:354–359, 1999.PubMedCrossRefGoogle Scholar
  4. 4).
    Gillett C, Fantl V, Smith R,et al: Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining.Cancer Res 54:1812–1817, 1994.PubMedGoogle Scholar
  5. 5).
    Gillett C, Smith P, Gregory W,et al:Cyclin Dl and prognosis in human breast cancer.Int J Cancer 69:92–99, 1996.PubMedCrossRefGoogle Scholar
  6. 6).
    Fredersdorf S, Burns J, Milne AM,et al: High level expression of p27kipl in proliferating tumour cells and its inverse correlation with the degree of malignancy in human breast colorectal tumours.Proc Natl Acad Sci USA 94:6380–6385, 1997.PubMedCrossRefGoogle Scholar
  7. 7).
    Gillett CE, Smith P, Peters G,et al: Cyclin dependent kinase inhibitor p27kipl expression and interaction with other cell cycle associated proteins in mammary carcinoma.J Pathol 187:200–206, 1999.PubMedCrossRefGoogle Scholar
  8. 8).
    Gullick WJ, Love SB, Wright C,et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.Br J Cancer 63:434–438, 1991.PubMedGoogle Scholar
  9. 9).
    Barnes DM, Dublin EA, Fisher CJ,et al: Immunohistochemical detection of p53 protein in mammary carcinoma; An important new independent indicator of prognosis.Human Pathol 24:469–476, 1993.CrossRefGoogle Scholar
  10. 10).
    Dublin EA, Miles DW, Rubens RD,et al: p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer.Int J Cancer (Pred Oncol) 74:605–608, 1997.CrossRefGoogle Scholar
  11. 11).
    Camplejohn RS, Ash C, Gillett CE,et al: The prognostic significance of DNA flow cytometry in breast cancer; Results from 881 patients treated in a single centre.Br J Cancer 71:140–145, 1995.PubMedGoogle Scholar
  12. 12).
    Korenman SG, Dukes BA: Specific estrogens binding by the cytoplasm of human breast carcinoma.Clin Endocrinol Metab 30:639–645, 1970.Google Scholar
  13. 13).
    Cooper LS, Gillett CE, Smith PE,et al: Cell proliferation measured by MIB1 and timing of surgery for breast cancer.Br J Cancer 77:1502–1507, 1998.PubMedGoogle Scholar
  14. 14).
    O’Reilly SM, Camplejohn RS, Barnes DM,et al: Nodenegative breast cancer; Prognostic subgroups defined by tumour size and flow cytometry.J Clin Oncol 8:2040–2046, 1990.PubMedGoogle Scholar
  15. 15).
    Nielsen NH, Emdin SO, Cajander J,et al: De-regulation of cyclin E and Dl in breast cancer is associated with inactivation of the retinoblastoma protein.Oncogene 14:295–304, 1997.PubMedCrossRefGoogle Scholar
  16. 16).
    Barnes DM, Gillett CE: Cyclin Dl in breast cancer.Br Cancer Res Treat 52:1–15, 1998.CrossRefGoogle Scholar
  17. 17).
    Barnes DM, Lammie GA, Millis RR,et al: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.Br J Cancer 58:448–452, 1988.PubMedGoogle Scholar
  18. 18).
    Barnes DM: c-erbB-2 amplification in mammary carcinoma.J Cell Biochem 17G:132–138, 1993.CrossRefGoogle Scholar
  19. 19).
    Bartkova J, Barnes DM, Millis RR,et al: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.Human Pathol 21:1164–1167, 1990.CrossRefGoogle Scholar
  20. 20).
    Barnes DM, Bartkova J, Camplejohn RS,et al: Overexpression of the c-erbB-2 oncoprotein; Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance.Eur J Cancer 28:644–648, 1992.PubMedCrossRefGoogle Scholar
  21. 21).
    Barnes DM, Camplejohn RS: p53, apoptosis and breast cancer.J Mam Gland Biol Neo 1:163–175, 1996.CrossRefGoogle Scholar
  22. 22).
    Houston SJ, Plunkett TA, Barnes DM,et al: Overexpression of c-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer.Br J Cancer 79:1220–1226, 1999.PubMedCrossRefGoogle Scholar
  23. 23).
    Allred DC, Harvey JM, Berardo M,et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol 11:155–169, 1998.PubMedGoogle Scholar
  24. 24).
    Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer; An overview of the randomised trials.Lancet 351:1451–1467, 1998.CrossRefGoogle Scholar
  25. 25).
    Baselga J, Seidman AD, Rosen PP,et al: HER2 overexpression and paclitaxel sensitivity in breast cancer; Therapeutic implications.Oncology ll(Suppl 2):43–48, 1997.Google Scholar
  26. 26).
    Yu D, Liu B, Tan M,et al: Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.Oncogene 13:1359–1365, 1996.PubMedGoogle Scholar
  27. 27).
    Slamon D, Leyland-Jones B, Shak S,et al: Addition of herceptin (humanised anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer multinational controlled phase III trial.Proceedings of the American Society of Clinical Oncology 17:98a, 1998.Google Scholar
  28. 28).
    Cardiff RD: Cellular and molecular aspects of neoplastic progression in the mammary gland.Eur J Cancer 24:15–21, 1988.CrossRefGoogle Scholar
  29. 29).
    Lampejo OT, Barnes DM, Smith P,et al: Evaluation of infiltrating ductal carcinomas with a DCIS component; Correlation of the histological type of the in situ component with grade of the infiltrating component.Semin Diag Pathol 11:215–222, 1994.Google Scholar
  30. 30).
    Millis RR, Barnes DM, Lampejo OT,et al: Does mammary tumour grade progress?; A study of the correlation between DCIS type, tumour grade and grade of recurrent breast carcinoma.Eur J Cancer 34:548–553, 1998.PubMedCrossRefGoogle Scholar
  31. 31).
    Roylance R, Gorman P, Harris W,et al: Comparative genomic hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer.Cancer Res 59:1433–1436, 1999.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1999

Authors and Affiliations

  • Diana M. Barnes
    • 1
  1. 1.Hedley Atkins/ICRF Breast Pathology Laboratory, Guy’s HospitalLondon

Personalised recommendations